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Summary Previous studies have shown that human leukaemic cells and certain tumour tissues have a higher
receptor-mediated uptake of low density lipoprotein (LDL) than the corresponding normal cells or tissues.
LDL has therefore been proposed as a carrier for anti-cancer agents. In the current study, a water-insoluble
mitoclomine derivative (WB 4291) was incorporated into LDL. The WB 4291 -LDL complex contained about
1,500 drug molecules per LDL particle and showed receptor-mediated toxicity in vitro as judged from the
difference in growth inhibitory effect on normal and mutant (LDL-receptor-negative) cultured Chinese hamster
ovary cells. However, cellular drug uptake did not exclusively occur by the receptor pathway since mutant cells
were also affected to some extent. The LDL part of the complex had the same plasma clearance and organ
distribution as native LDL after i.v. injection in mice and rabbits. Therapeutic effects were observed when
Balb-C mice with experimental leukaemia were treated with the complex. After i.p. administration to mice
with i.p. leukaemia median survival time was prolonged 2.5-fold and 40% became long time survivors. The
effect was weaker (42% increase in life span) after i.v. injections of the complex to mice with i.v. leukaemia.
In order to increase the anti-neoplastic effects and reduce
toxic effects on normal cells, attempts have been made to
administer cancer chemotherapeutic agents linked to carriers
like antibodies, liposomes, hormones and other macro-
molecules (Eisenbrand et al., 1989; Gregoriadis, 1976a,b;
Hurwitz et al., 1975; Kaneko, 1981; Morgan et al., 1989; Rao
et al., 1989; Trouet et al., 1972). A major problem in vivo has
been the rapid clearance of such complexes from the blood-
stream because they are recognised as foreign material by
cells of the reticulo-endothelial system in the liver and the
spleen.
We have focused our attention on the possibility of using
the endogenous carrier for cholesterol, low density lipo-
protein (LDL), for drug targeting in leukaemia and other
malignancies. LDL contains approximately 75% of plasma
cholesterol in humans. An LDL particle contains a lipid core
of about 1,500 cholesteryl ester molecules surrounded by a
polar shell of free cholesterol, phospholipids, and protein
(Goldstein & Brown, 1977). The protein (apoprotein B)
interacts with specific cell surface receptors (Goldstein &
Brown, 1977). After binding to the receptor, LDL is inter-
nalised and degraded in lysosomes. The lipid core of LDL
yields unesterified cholesterol, which is used for membrane
synthesis or as a precursor in steroid hormone synthesis. The
rationale for using LDL as a carrier for cytotoxic drugs is
that certain human leukaemic cells and tumour tissues have
higher LDL receptor activity than the corresponding normal
cells or tissues (Gal et al., 1981; Ho et al., 1978; Hynds et al.,
1984; Norata et al., 1984; Vitols et al., 1984a).
We have shown in previous studies that it is possible to
incorporate the lipophilic doxorubicin derivative N-
trifluoroacetyl-adriamycin-14-valerate (AD-32) into LDL
without interfering with the in vivo behaviour of LDL in mice
(Masquelier et al., 1986). The key step in the incorporation
procedure was found to be lyophilisation of LDL in the
presence of sucrose as protective agent.
In the current paper we demonstrate that it is possible to
incorporate a lipophilic alkylating agent into LDL. The com-
plex exerted receptor-mediated growth inhibition on cultured
cells and the in vivo behaviour was unaltered as compared to
native LDL. Moreover, the complex showed therapeutic
activity on mice with experimental leukaemia.
Methods
Materials
Sodium '25I (carrier free, pH 7-11) was purchased from the
Radiochemical Centre (Amersham, UK). Naphthylnitrogen-
mustard (code number designation WB4291, Figure 1) was
supplied by Boehringer Ingelheim (UK). Tissue culture Petri
dishes, 35 x 10 mm, were from Becton Dickinson and Co.
(Oxnard, CA, USA) and 90cm2 tissue culture flasks were
from A/S Nunc (Roskilde, Denmark). Fetal calf serum, tissue
culture medium, and other cell culture equipment were from
sources previously reported (Masquelier et al., 1986; Vitols et
al., 1985a). MILLEX HA (0.45pm) filters were from Milli-
pore, SA (Molsheim, France). Bovine serum albumin (frac-
tion V) was from Sigma Chemical Co. (St Louis, MO, USA).
Sephadex G-20 columns (PD-10) were from Pharmacia (Upp-
sala, Sweden).
Lipoproteins
Human LDL (density 1.020-1.063 g ml-') was isolated from
serum from healthy blood donors by sequential ultracentri-
fugation as described by Havel et al. (1955). Human lipo-
protein deficient serum (LPDS, density > 1.215 gml-') was
prepared as previously described (Vitols et al., 1984b).
Methylated LDL was prepared as described by Weisgraber et
H3
Figure 1 Chemical structure of WB 4291.
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al. (1978) and '251I-LDL was prepared as described by Langer
et al. (1972). Before use it was always checked that
methylated LDL did not inhibit cellular uptake and degrada-
tion of 1251-LDL. The purity of LDL was checked by agarose
gel electrophoresis. All concentrations of LDL given refer to
protein.
Incorporation ofdrug into LDL
WB 4291 was incorporated into LDL in principle as
previously described for the cytotoxic drug N-trifluoro-
acetyladriamycin-14-valerate (AD-32), the key step being the
lyophilisation of LDL in the presence of sucrose as protect-
ing agent (Masquelier et al., 1986). Briefly, after dialysis
against 0.3 mM NaEDTA, 2 mg of '25I-LDL in a volume of
400 plA was transferred to a glass tube containing 20 mg suc-
rose. The solution was rapidly frozen in liquid nitrogen and
lyophilised over night. The dried '25I-LDL was extracted
three times with heptane after which 0.2-6 mg of WB 4291
in 200 pl of heptane was added. After evaporation of the
solvent, 1 ml of phosphate buffered saline (PBS,
140 mM NaCl, 2.7 mM KCI, 9.5 mM KH2PO4, 9.5 mM
Na2HPO4, pH 7.4) was added. Insoluble drug was removed
by centrifugation, after which the preparation was passed
through a Sephadex G-20 column to remove any water-
soluble, non-incorporated metabolites of the drug. This step
usually lowered the drug content in the preparation by 10%.
The complexes were finally passed through a MILLEX
0.45 ltm filter and stored (<1 week) in the dark at + 4°C.
When large amounts of drug-LDL complex were needed,
lyophilisation and subsequent steps were carried out in a
round-bottomed glass flask.
In one experiment the incorporation method of Krieger et
al. (1979), in which LDL is lyophilised in the presence of
insoluble starch, was used for comparison.
Cell incubations
All cells were maintained in a humidified incubator (5% CO2,
95% air) at 37C in RPMI-1640 medium supplemented with
antibiotics (100 IU penicillin + 100 ig streptomycin ml'), L-
glutamine (2 mM) and 10% fetal calf serum (FCS).
WEHI-3B cells, a murine myelomonocytic leukaemia cell
line possessing a high number of LDL-receptors (Masquelier
et al., 1986), were grown in suspension culture. For
experiments, cells in exponential growth at a concentration
of about 2 x 106ml1' of cell culture medium with 10% FCS
in 90 cm2 stock flasks were transferred to 50 ml sterile Falcon
plastic tubes and centrifuged at 500g for 5 min. The medium
was discarded and the cell pellet was suspended in medium
containing 10% LPDS and recentrifuged. The supernatant
was again discarded and the cells diluted to a concentration
of 1.5 x 106mlP' in the same medium and incubated in
90cm2 stock flasks at 37°C. After 36 hours the cells were
transferred to sterile plastic 50 ml Falcon tubes and centri-
fuged. Preincubation under these conditions increased the
receptor-mediated uptake of '251-LDL by the cells 5-10-fold.
The cells were then diluted to approximately 35 x 106
cells ml1' in Hepes-buffered RPMI-1640 with 10% LPDS
and 0.5 ml aliquots of the cell suspensions with the indicated
additions were transferred to sterile 10 ml round-bottom
glass tubes and incubated at 37°C in a shaking water bath.
After 4 h, the incubation was terminated by diluting the cells
in medium containing 10% FCS to a final concentration of
50,000 cells ml -'. Two ml aliquots were transferred to
35 x 10 mm Petri dishes and the cells were allowed to grow
at 37°C. After different time periods aliquots were taken and
the cells counted.
The in vitro toxicity of WB 4291 -LDL was also studied on
normal and mutant (LDL-receptor-negative) Chinese hamster
ovary cells (CHO cells, kind gift from Dr Monty Krieger,
Massachusetts Institute of Technology, Boston, MA, USA)
grown in monolayer culture. Confluent cells in 90 cm2 tissue
culture flasks were detached with 0.05% trypsin and 0.02%
EDTA and seeded (day 0) at a concentration of about
250,000 cells per 35 x 10 mm Petri dish. On day 2 the
medium was discarded, the cells washed with 1 ml of medium
with 2% LPDS and 1 ml of fresh medium containing 10%
LPDS was added to induce a high LDL-receptor activity. On
day 3, when the cells were subconfluent, the incubation was
started by adding fresh medium containing 10% LPDS and
the indicated concentration of drug-LDL complex. After
21 h, the incubation was terminated by discarding the
medium and washing the cells with 1 ml of PBS after which
the cells were detached with trypsin/EDTA and diluted 30
times in medium with 10% FCS. Finally, 1 ml aliquots of the
cell suspensions were transferred to new 35 x 1Omm Petri
dishes and the cells were allowed to grow. After 3 days the
medium was discarded, the cells detached, and counted in a
Linson 431 A cell counter. The doubling time for both cell
strains was approximately 1Oh.
In vivofate of WB4291-LDL
The in vivo studies were performed on male Balb-C mice
(20-25 g) and male white New Zealand rabbits (2.0-2.5 kg).
Each mouse received an i.v. injection of 25pg '25I-LDL or
WB 4291-'25I-LDL. After 90min, the animals were killed,
and the radioactivity was measured in plasma and various
organs. Relative tissue uptake of '25I-LDL was calculated by
dividing the radioactivity per gram of organ by the total
plasma radioactivity at the time of death as described
previously (Masquelier et al., 1986). The plasma volume was
assumed to be 4% of the animal weight. The in vivo
behaviour of the complex was also determined from the
plasma disappearance rate of radioactivity in rabbits. Before
the experiment, the rabbits were given drinking water with
KI (0.1 gl-') for 2 days. Each animal received an i.v. injec-
tion of approximately 300 lag of '25I-LDL or the complex in a
marginal ear vein. Blood samples were taken after different
time periods from the opposite ear by a small incision in the
marginal vein. The radioactivity in plasma after 10 min was
used to calculate the plasma volume.
Therapeutic activity of WB4291-LDL
lp.-i.p. schedule On day 0, each Balb-C mouse (weight
17-20 g) received 106 WEHI-3B cells. The complex was given
twice daily on days 1-4.
I.v.-i.v schedule On day 0 each Balb-C mouse (weight
22-23 g) received 104 WEHI-3B cells. The complex was given
twice daily, on days 1-3.
In both types of experiments, animal weight and survival
were recorded.
Assays
The WB 4291 concentration in LDL complexes was
measured by HPLC analysis using a 15 cm Nucleosil Phenyl
7 lm column eluted with 60% acetonitrile in 0.2%
ammonium formate, pH 4.0, at a flow rate of 1.5 ml min-'.
Drug concentration was quantitated using a Shimadzu SPD-
6A u.v. detector at 297 nm. A total of 320pl of a drug-LDL
complex was precipitated with 600ftl 100% acetonitrile after
which 80ftl 1% ammonium formate pH 4.0 was added. Fol-
lowing low-speed centrifugation the supernatant was injected
directly into the column. Standards were prepared by dissolv-
ing WB 4291 directly in mobile phase. Unidentified
metabolites were quantitated as drug equivalents, assuming
identical u.v. absorption properties. '25I radioactivity was
determined in a Packard AUTO GAMMA model 800 C
y-counter. The particle size of native LDL and drug-LDL
complexes was measured by quasi-elastic light scattering (dis-
tribution of mass) on a Malvern Autosizer llc, (Malvern
Instruments, Malvern, UK). Protein concentration was deter-
mined by the method of Lowry et al. (1951) using bovine
serum albumim as standard. Alternatively, protein concentra-
tion in drug-LDL complexes was calculated from radioac-
tivity, using the specific activity of '25I-LDL.726 S. VITOLS et al.
Results
Characterisation of WB4291-LDL
To study the stoichiometry of the incorporation procedure
we added different amounts of WB 4291 to fixed amounts of
lyophilised LDL (Figure 2). As the amount of drug was
increased, the drug/LDL-protein ratio of the complex
increased until a plateau at approximately 600pg WB 4291
per mg LDL (1,500 drug molecules per LDL particle) was
approached. HPLC analysis revealed that the mother com-
pound constituted more than 95% of the incorporated drug.
Protein recovery was about 60-85% whereas the recovery of
drug was 10-20%. Figure 3a-c shows electron micrographs
of native LDL and WB 4291-LDL complexes prepared by
the current method and by the method of Krieger et al.
(1979). Particle size measurements revealed that the complex
prepared by the current method had almost the same size as
native LDL (Table I) while WB 4291-LDL prepared accord-
ing to Krieger et al. resulted in larger and more polydisperse
particles.
Stability ofWB 4291-251I-LDL was tested by incubation in
human and rabbit blood. Approximately 95% of the added
radioactivity and drug content was found in the plasma
following a 1 h incubation at 37°C with whole human blood.
Ultracentrifugation of the plasma at the density 1.21 g 1'
showed that the lipoprotein depleted fraction contained less
than 5% of the drug content in the plasma, the remainder
was recovered in the lipoprotein containing top fraction. The
distribution of drug and radioactivity in rabbit plasma fol-
lowing a 1 h incubation with the complex was roughly the
same.
In vitro toxicity of WB4291-LDL
The toxic effect of the complex towards cultured cells was
studied in the presence and absence of native LDL or
methylated LDL. If the drug is tightly bound to LDL, then
excess native LDL should compete with the complex for
binding to the LDL receptor and hence reduce uptake and
toxicity of the complex. Methylated LDL, which does not
bind to the LDL receptor, should not have this counteracting
effect. Figure 4 demonstrates that the growth inhibitory effect
of the complex on WEHI-3B cells was counteracted by a
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Figure 2 Effect of increasing amounts of WB4291/freeze dried
LDL on the mass ratio of the recovered WB4291-LDL com-
plex.
Table I Particle size of native LDL and drug-LDL complexes
measured by quasi-elastic light scattering
Diameter (nm)
Preparation (mean; s.d.)
Native LDL (n = 5) 22.5; 0.84
WB 4291 -LDL (n =4) 24.4; 0.62
WB 4291 -LDL (Krieger, n = 3) 47.1; 13.0
Figure 3 Electron micrographs of a, native LDL, b,
WB 4291 -LDL prepared with the current method, and c,
WB 4291 -LDL prepared by the technique described by Krieger
et al. (1979). The LDL preparations were applied to carbonform-
var membranes and negatively stained with 2% phosphotungstate
solution. They were examined on a Philips EM301 instrument at
a magnification of 40,000 x.
In order to study further the mechanism behind the growth
inhibitory effect, normal and mutant (LDL receptor-negative)
CHO-cells were incubated with the complex. As shown in
Figure 5, the complex was more toxic towards the normal
than the mutant cells. The difference was more pronounced
at low concentrations (<1 1tgml-').
In vivo behaviour of WB4291-'25I-LDL
Figure 6 shows the radioactivity in plasma and various
organs from mice 90 min after an i.v. injection of '25l-LDL or
the labelled complex. The '25I-LDL part of the complex
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behaved quite like native "5I-LDL. In rabbits, the decay of
plasma radioactivity was almost identical for '25I-LDL and
WB 4291 -'25I-LDL (Figure 7). In contrast, when WB 4291
was incorporated into 125I-LDL using the method of Krieger
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Figure 4 Time course for the growth of WEHI-3B cells which
had been exposed to WB4291 -LDL (0.58ggml-' of WB4291,
1 jig ml- of protein) for 4 h in the presence and absence (0) of
250 tg ml1- of native (A) or methylated (A) LDL. Control (0).
The pulse incubation was ended by diluting the cells 700 times to
a final concentration of 50,000 cells ml ' (day 0 on time scale).
Each point shows the mean of two experiments; the variation was
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Figure 5 Growth inhibition (% of control) of normal (0) and
mutant (0) CHO-cells 72 h after a pulse incubation (duration
21 h) with the indicated concentrations of WB 4291-LDL. Con-
centrations of drug-LDL complex refer to LDL-protein. One mg
of LDL-protein corresponds to 580gg of WB 4291. The pulse
incubation was ended by washing and detaching the cells and
seeding the detached cells at low cell concentration (50,000 cells
per 35 x 10 mm Petri dish). Each point shows the mean of two





Figure 6 Radioactivity in plasma expressed as percentage of the
injected dose and relative tissue uptake expressed as radioactivity
per gram organ divided by the total radioactivity in plasma
90 min after i.v. injection of native "5I-LDL (0) or
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Figure 7 Time course for plasma radioactivity in rabbits after
i.v. injection of native "5I-LDL (0) or WB 4291-"'5I-LDL
prepared by the sucrose method (0) or the method of Krieger
and co-workers (A). Each point represents the mean value of two
animals.
Therapeutic activity of WB4291-LDL
When given i.p., the complex had a therapeutic effect on mice
with experimental i.p. leukaemia (Figure 8). During the treat-
ment period (240 yg WB 4291 x 2 x IV), the average weight
loss for the mice was 15%. Median survival time for the
control group was 17 days and for the treatment group 40
days. After 60 days, 40% of the treated animals were still
alive with no signs of recurrent disease.
The therapeutic effect of the complex given i.v. to mice
with experimental i.v. leukaemia was weaker (Figure 9).
Three dose levels were investigated. At the highest dose
(560;Lg WB 4291 x 2 x III) survival increased 42% whereas
toxicity was pronounced (average weight loss 41%). At the
lower dose levels of WB 4291 (280 Lg and 140gg x 2 x III)
the increase in life span was 24% and 9%, respectively, and
weight loss was minimal (<7%).
Discussion
In the current paper, we demonstrate that it is possible to
incorporate a lipophilic cytotoxic mitoclomine derivative into
LDL. The incorporation procedure was reproducible and did
not denature the lipoprotein to any significant extent. Two
types of evidence are presented to show that the drug
inhibited cell growth following receptor-mediated uptake of
I the drug-LDL complex. Firstly, the growth inhibition of




Figure 8 Survival of mice with i.p. leukaemia treated with
WB 4291 -LDL i.p. (240jg of WB 4291 given twice daily during
days 1-4; 240fig WB 4291 corresponded to 400jug of LDL-
protein). The mice in the control group received buffer only. Ten
animals in each group. Arrows indicate drug-LDL complex injec-
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Figure 9 Survival of mice with i.v. leukaemia treated with three
different dose levels of WB 4291 -LDL ( 560 'g 280 jig,
or 140 pg of WB 4291 given twice daily during days 1-3;
560pg of WB 4291 corresponded to 1.6mg of LDL-protein).
Controls ( ). Three animals in each group.
the presence of excess native LDL but not by methylated
LDL. Secondly, the complex exerted differential toxicity
towards normal and mutant (receptor-negative) CHO-cells.
At high concentrations of the complex mutant cells were also
killed, indicating that non-specific drug uptake occurred. Pos-
sible explanations are drug leakage from the complex fol-
lowed by diffusion into the cells and/or bulk fluid endocytosis
by the cells.
A prerequisite for successful drug-targeting is that the
drug-carrier complex is not recognised as non-self by the
reticulo-endothelial system in liver and spleen which would
lead to rapid clearance from the bloodstream. I.v. injections
of WB 4291d-LDL in mice and rabbits clearly demonstrated
that the LDL part of the complex had the same plasma
clearance rate and organ distribution as native human LDL.
Several other methods have been proposed for the incor-
poration of lipophilic toxic substances into LDL (Krieger et
a!., 1979; Iwanik t al., 1984; Lundberg, 1987). However,
these investigators did not show that their drug-LDL com-
plexes have the same plasma clearance rate as native LDL.
In a previous paper we reported that the anthracycline
derivative AD 32 could be incorporated into LDL with the
current method using sucrose as protecting agent (Masquelier
et al., 1986). This complex also had a normal in vivo
behaviour after i.v. injection in mice. However, AD 32 is a
more polar drug than WB4291 and the number of incor-
porated drug molecules was 100-150 per LDL particle which
is of the order of ten times lower than for WB 4291. Conse-
quently, our interest focused on WB4291 which was thus
about ten times more potent (on a LDL protein concentra-
tion basis) in inhibiting growth of WEHI-3B cells in vitro.
It would of course be desirable to compare the therapeutic
and toxic effects of WB 4291 in free form and as LDL
complex. However, this cannot easily be done since the drug
is water insoluble, and would have to be dissolved in an
organic solvent or oil which would make the comparison
with the complex unfair. Nevertheless, we have shown that a
drug-LDL complex prepared from a water insoluble drug
exerts therapeutic activity in vivo after i.v. and i.p. injections
in leukaemic mice.
Animals generally have low levels of plasma LDL, and it
might be suggested that when the complex is administered to
humans, endogenous LDL in the circulation will compete for
the LDL receptors on malignant cells and consequently
reduce the anti-tumoral effect of the complex. However,
patients with acute myelogenous leukaemia have low
cholesterol levels at diagnosis (Vitols et al., 1985b; Budd &
Ginsberg, 1986), most likely as a consequence of the high
receptor-mediated uptake of LDL by leukaemia cells.
Plasmapheresis could perhaps also be used to reduce
endogenous LDL levels.
Another objection that can be raised is that organs like the
liver and adrenals which are known to be the normal tissues
with the highest LDL uptake would suffer during treatment
with drug-LDL complexes. This problem might be circum-
vented since animal studies indicate that it is possible to
down-regulate the LDL-uptake in these organs by pretreat-
ment with bile acids and steroids without affecting the uptake
by the tumour (Hynds et al., 1984).
Several highly lipophilic compounds with promising
cytotoxic effects in vitro have never reached clinical trials
because of difficulties in finding a suitable non-toxic. solvent.
LDL might prove to be an interesting and simple delivery
system to administer these compounds.
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